CVS acquisition of Aetna may not face antitrust challenges

U.S. antitrust enforcers might not move to block CVS Health’s acquisition of health insurance company Aetna, Bloomberg reported. The news, which was fueled from a report by Reorg Research, spiked shares of both companies last week.

Justice Department staff are expected to support approval of the $69 billion deal, which was announced in December 2017 and approved by shareholders of both companies in March.

Read the full story below:

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

With generative AI coming into its own, AI regulators must avoid relying too much on principles of risk management—and not enough on those of uncertainty management.

Cardiovascular devices are more likely to be in a Class I recall than any other device type. The FDA's approval process appears to be at least partially responsible, though the agency is working to make some serious changes. We spoke to a researcher who has been tracking these data for years to learn more. 

Updated compensation data includes good news for multiple subspecialties. The new report also examines private equity's impact on employment models and how much male cardiologists earn compared to females.

Trimed Popup
Trimed Popup